Can a gentle energy device turn down fibromyalgia pain?
NCT ID NCT07769177
First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time
Summary
This trial tests whether TECAR therapy, a non-invasive device that delivers energy to painful areas, can reduce pain in people with fibromyalgia. About 46 adults with fibromyalgia will receive either real or sham TECAR sessions twice a week for three weeks. Researchers will measure changes in pain, sleep quality, and quality of life to see if the therapy offers meaningful relief.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- TECAR therapy, a device-based treatment using capacitive and resistive energy transfer to painful areas
- What this could lead to
- If effective, TECAR therapy could offer a drug-free option to reduce pain and improve sleep and daily function in people with fibromyalgia.
- What could go wrong
- This is a small early-stage trial, and the sham control may produce similar effects. Results may not apply to all fibromyalgia patients, and benefits could be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
46 people
The number who actually took part.
- Started
-
Apr 2025
- Finished
-
Jun 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age between 18 and 65 years * Diagnosed with fibromyalgia syndrome (FMS) according to the 2016 American College of Rheumatology (ACR) diagnostic criteria * Willing and able to provide written informed consent Exclusion Criteria: * Pregnancy * Deep vein thrombosis (DVT) * Presence of a cardiac pacemaker * Inflammatory rheumatic diseases * Psychiatric disorders * Medical or physical therapy treatment for fibromyalgia (FM) within the last 3 months * Skin conditions in the application area * History of active malignancy or malignancy within the past year, and ongoing chemotherapy and/or radiotherapy * Active infection or coagulation disorders * Uncontrolled or severe cardiovascular or metabolic disorders * Significant disc herniation, radiculopathy, myelopathy, or neurological deficit
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fibromyalgia (FM) or fibromyalgia syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Üniversiteler Mahallesi, Bilkent Caddesi, No: 1 (veya 6000. Cadde, No: 9) Çankaya Ankara Turkey
Ankara, 06, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.